米国の炎症性腸疾患治療市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年-2030年

米国の炎症性腸疾患治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の炎症性腸疾患治療市場規模は2030年までに141億米ドルに達すると予測され、2024年から2030年までのCAGRは2.5％で成長すると予測されています。

米国全体で潰瘍性大腸炎とクローン病の有病率が上昇していることが、予測期間中の市場成長を促進すると予測されています。炎症性腸疾患（IBD）の発症には、遺伝的素因、免疫系の機能障害、環境要因、腸内細菌叢のアンバランス、生活習慣要因の組み合わせが影響していると考えられます。2023年に発表された論文によると、炎症性腸疾患はアメリカ人の0.7％以上が罹患する比較的一般的な慢性疾患であり、北東部地域で最も流行しています。このような患者数の増加により高度な治療オプションが必要となり、市場の成長を牽引しています。

クローン病・大腸炎財団は、炎症性腸疾患に苦しむ患者の生活の質を向上させるため、製品開発の強化に取り組んでいます。同財団は、製品志向の研究開発を支援するため、専用の資金提供システムであるベンチャーを立ち上げています。

2023年9月、武田薬品は、クローン病治療薬ENTYVIO（一般名：vedolizumab）の皮下投与に関する生物製剤承認申請（BLA）をFDAが受理したと発表しました。規制当局の承認は、新薬、生物製剤、医療機器の市場参入に道を開くものです。これにより、IBD患者の治療選択肢が広がり、治療成績やQOLが改善する可能性があります。

米国炎症性腸疾患治療市場レポート・ハイライト

• タイプ別では、クローン病分野が2023年に最大の売上高シェアで市場を独占しました。この大きなシェアは、消化管に影響を及ぼし、腹痛、下痢、体重減少、倦怠感などの症状を引き起こすクローン病の慢性炎症性により、より多くの治療選択肢と進歩が求められているためです。
• 一方、潰瘍性大腸炎は、その罹患率の増加により、予測期間中に最も速いCAGRを記録すると予想されています。
• 薬剤クラス別では、TNF阻害薬が症状の管理と炎症の抑制に有効であることから、2023年の市場売上高シェアはTNF阻害薬が最大でした。
• 投与経路別では、注射薬が2023年に最大の市場シェアを占めました。生物製剤やバイオシミラーなどの注射薬は、炎症性腸疾患の炎症プロセスに関与する特定のタンパク質や細胞を標的とするように設計されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の炎症性腸疾患治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の炎症性腸疾患治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の炎症性腸疾患治療市場：タイプ推定・動向分析

• タイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• 米国の炎症性腸疾患治療市場（タイプ別）の見通し
• 2018年から2030年までの市場規模と予測および動向分析

第5章 米国の炎症性腸疾患治療市場：薬剤クラスの推定・動向分析

• 薬物クラス市場シェア、2023年および2030年
• セグメントダッシュボード
• 米国の炎症性腸疾患治療市場の薬剤クラス別展望
• 2018年から2030年までの市場規模と予測および動向分析
• アミノサリチル酸塩
• コルチコステロイド
• TNF阻害剤
• IL阻害剤
• 抗インテグリン
• JAK阻害剤

第6章 米国の炎症性腸疾患治療市場：投与経路の推定・動向分析

• 投与経路の市場シェア、2023年と2030年
• セグメントダッシュボード
• 米国炎症性腸疾患治療市場：投与経路別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 経口
• 注射

第7章 米国の炎症性腸疾患治療市場：流通チャネルの推定・動向分析

• 流通チャネル市場シェア、2023年および2030年
• セグメントダッシュボード
• 米国の炎症性腸疾患治療市場：流通チャネル別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 院内薬局
• 小売り薬局
• オンライン薬局

第8章 米国の炎症性腸疾患治療市場：地域推定・動向分析

• 地域別市場シェア、2023年および2030年
• 米国の炎症性腸疾患治療市場：地域別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 西部
• 中西部
• 北東部
• 南西部
• 南東部

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
• 企業プロファイル
  • Biogen
  • Novartis AG
  • Eli Lilly &Company
  • UCB SA
  • Celltrion Inc.
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. inflammatory bowel disease treatment market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. inflammatory bowel disease treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 4 U.S. inflammatory bowel disease treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 U.S. inflammatory bowel disease treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. inflammatory bowel disease treatment market, by region, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. inflammatory bowel disease treatment market: market outlook
• Fig. 9 U.S. Inflammatory bowel disease treatment competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 U.S. inflammatory bowel disease treatment market driver impact
• Fig. 14 U.S. inflammatory bowel disease treatment market restraint impact
• Fig. 15 U.S. inflammatory bowel disease treatment market: Type movement analysis
• Fig. 16 U.S. inflammatory bowel disease treatment market: Type outlook and key takeaways
• Fig. 17 Crohn's Disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Ulcerative Colitis estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 U.S. inflammatory bowel disease treatment market: Drug class movement analysis
• Fig. 20 U.S. inflammatory bowel disease treatment market: Drug class outlook and key takeaways
• Fig. 21 Aminosalicylates market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 TNF inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 IL inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Anti-integrin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 JAK inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 U.S. inflammatory bowel disease treatment market: Route of administration movement analysis
• Fig. 28 U.S. inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
• Fig. 29 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 U.S. inflammatory bowel disease treatment market: Distribution channel movement analysis
• Fig. 32 U.S. inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
• Fig. 33 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 U.S. inflammatory bowel disease treatment market: Regional movement analysis
• Fig. 37 U.S. inflammatory bowel disease treatment market: Regional outlook and key takeaways
• Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

• Based on type, the Crohn's disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
• On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.
• Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type
  • 2.2.2. Drug Class
  • 2.2.3. Route of Administration
  • 2.2.4. Distribution Channel
• 2.3. Competitive Insights

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Inflammatory Bowel Disease Treatment Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 4.4.1. Crohn's Disease
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Ulcerative Colitis
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Drug Class Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 5.4.1. Aminosalicylates
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Corticosteroids
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. TNF Inhibitors
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. IL Inhibitors
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Anti-integrin
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. JAK Inhibitors
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 6.4.1. Oral
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Injectable
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 7.4.1. Hospital Pharmacy
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Retail Pharmacy
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. Online Pharmacy
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment Market: Region Estimates & Trend Analysis

• 8.1. Regional Market Share, 2023 & 2030
• 8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
• 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 8.3.1. West
    • 8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.3.2. Midwest
    • 8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Northeast
    • 8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.4. Southwest
    • 8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.5. Southeast
    • 8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company heat map analysis, 2023
• 9.4. Company Profiles
  • 9.4.1. Biogen
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Novartis AG
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eli Lilly & Company
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. UCB S.A.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Celltrion Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Merck & Co., Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Johnson & Johnson Services, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives